Zach Reitano

Zach Reitano, CEO of telehealth platform Ro, discusses the booming GLP-1 drug marketplace and its economic implications. He highlights how these medications could transform obesity treatment by changing eating habits and healthcare dynamics. In contrast, Dr. Robert Lustig, an endocrinologist from UCSF, raises skepticism about their efficacy and long-term health impacts, emphasizing potential side effects like nausea. The conversation challenges traditional views on weight management and stresses the importance of equitable access and multifaceted treatment approaches.

Zach Reitano, entrepreneur focused on personalized healthcare, shares how Covid accelerated telemedicine adoption, the importance of building trust with patients, and the impact of Ro's commercial featuring his dad.

Zach Reitano, CEO and co-founder of Ro, a direct-to-patient healthcare company, discusses the challenges in today's healthcare model. He highlights how the system often overlooks patient needs and the importance of focusing on cost, quality, and access. Reitano shares insights into using technology to enhance care and argues that quality should not be equated with time spent. He champions a patient-centric approach, advocating for empowered health choices and innovative financial solutions like healthcare savings accounts to foster autonomy.